| HOME >> MEDICINE >> TECHNOLOGY |
- RecordAF Registry Baseline Data and New Data from the Landmark ATHENA
Study
PARIS, Nov. 4 /PRNewswire/ --
Live Webcast Media Briefing - non-US media only
Wednesday 12 November 2008 - 14.00-15.00am CET
Background:
-- AF is a growing health concern directly responsible for increased
morbidity and mortality
-- There is a need for a global prospective database like RecordAF, which
takes a closer look at disease characteristics and how management of AF
affects cardiovascular (CV) outcomes
-- AF is associated with a high hospitalization burden - 70 percent of AF
management costs are driven by hospitalization costs (Ringborg et al.
Europace 2008; 10:403-11)
-- A further sub-analysis of the ATHENA trial was conducted:
-- to better understand the impact of dronedarone on hospitalization
of AF patients particularly on the number and duration of CV and
non CV hospitalization nights
-- An additional sub-analysis was also conducted to further explore
dronedarone's rhythm and rate controlling properties
-- The ATHENA study is the first AF trial designed to evaluate the effect
of an anti arrhythmic drug (AAD) on morbidity and mortality. It showed
that dronedarone (brand name Multaq(R)), a new AAD undergoing the
registration process, can significantly improve CV outcomes including
reducing the risk of hospitalization and death.
Register on-line in advance of the online event:
1. Go to
https://sanofiaventismediabriefing.webex.com/sanofiaventismediabriefing/ons
t
age/g.php?d=702842657&t=a&EA=nburns%40webex.com&ET=6b1f2c181b8fa5176928ed1c
72 009c4d&ETR=8789fb6f20765cb360e4d0c88cea0f23 (due to the length of this
URL, please copy a
'/>"/>
| SOURCE Sanofi-aventis Copyright©2008 PR Newswire. All rights reserved |